Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients.

Sigalotti L, Covre A, Fratta E, Parisi G, Sonego P, Colizzi F, Coral S, Massarut S, Kirkwood JM, Maio M.

J Transl Med. 2012 Sep 5;10:185. doi: 10.1186/1479-5876-10-185.

2.

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients.

Sigalotti L, Fratta E, Bidoli E, Covre A, Parisi G, Colizzi F, Coral S, Massarut S, Kirkwood JM, Maio M.

J Transl Med. 2011 May 26;9:78. doi: 10.1186/1479-5876-9-78.

3.

Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.

Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N.

Gynecol Oncol. 2005 Mar;96(3):651-7.

PMID:
15721407
4.

Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients.

Brunner G, Reitz M, Schwipper V, Tilkorn H, Lippold A, Biess B, Suter L, Atzpodien J.

Cancer Biother Radiopharm. 2008 Aug;23(4):451-9. doi: 10.1089/cbr.2008.0473.

PMID:
18771349
5.

Analysis of FIGO Stage IIIc endometrial cancer patients.

McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R.

Gynecol Oncol. 2001 May;81(2):273-8.

PMID:
11330962
6.

Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma.

Jiang W, Liu N, Chen XZ, Sun Y, Li B, Ren XY, Qin WF, Jiang N, Xu YF, Li YQ, Ren J, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Mai HQ, Zeng MS, Kang TB, Jia WH, Shao JY, Ma J.

Mol Cancer Ther. 2015 Dec;14(12):2864-73. doi: 10.1158/1535-7163.MCT-15-0260. Epub 2015 Oct 6.

7.

Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.

Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E.

BMC Cancer. 2009 Jul 1;9:217. doi: 10.1186/1471-2407-9-217.

8.

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2009 Jul;58(7):1085-94. doi: 10.1007/s00262-008-0631-1. Epub 2008 Nov 28.

PMID:
19039588
9.

Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.

Ishihara K, Saida T, Otsuka F, Yamazaki N; Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society.

Int J Clin Oncol. 2008 Feb;13(1):33-41. doi: 10.1007/s10147-007-0751-1. Epub 2008 Feb 29.

PMID:
18307017
10.

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.

PMID:
22382007
12.

Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.

Ito T, Wada M, Nagae K, Nakano-Nakamura M, Nakahara T, Hagihara A, Furue M, Uchi H.

J Eur Acad Dermatol Venereol. 2015 May;29(5):912-8. doi: 10.1111/jdv.12722. Epub 2014 Sep 8.

PMID:
25199412
13.

The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis.

Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR.

Clin Cancer Res. 2006 Aug 1;12(15):4605-13.

14.

Survival-related profile, pathways, and transcription factors in ovarian cancer.

Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG.

PLoS Med. 2009 Feb 3;6(2):e24. doi: 10.1371/journal.pmed.1000024.

15.

Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients.

Ezzat AA, Ibrahim EM, El Weshi AN, Khafaga YM, AlJurf M, Martin JM, Ajarim DS, Bazarbashi SN, Stuart RK, Zucca E.

Head Neck. 2001 Jul;23(7):547-58.

PMID:
11400243
16.

Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM.

Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9.

17.

Aberrant methylation of the VIM promoter in uterine cervical squamous cell carcinoma.

Lee MK, Jeong EM, Kim JH, Rho SB, Lee EJ.

Oncology. 2014;86(5-6):359-68. doi: 10.1159/000362738. Epub 2014 Jun 12.

PMID:
24942637
18.

Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.

Rauh-Hain JA, Growdon WB, Schorge JO, Goodman AK, Boruta DM, McCann C, Horowitz NS, del Carmen MG.

Gynecol Oncol. 2010 Nov;119(2):299-304. doi: 10.1016/j.ygyno.2010.07.010. Epub 2010 Aug 5.

PMID:
20691465
19.

Is sex an independent prognostic factor in cutaneous head and neck melanoma?

Arce PM, Camilon PR, Stokes WA, Nguyen SA, Lentsch EJ.

Laryngoscope. 2014 Jun;124(6):1363-7. doi: 10.1002/lary.24439. Epub 2013 Nov 7.

PMID:
24122966
20.

Association of TIMP3 expression with vessel density, macrophage infiltration and prognosis in human malignant melanoma.

Das AM, Koljenović S, Oude Ophuis CM, van der Klok T, Galjart B, Nigg AL, van Cappellen WA, Noordhoek Hegt V, Dinjens WN, Atmodimedjo PN, Vermeulen CE, Verhoef C, Eggermont AM, ten Hagen TL.

Eur J Cancer. 2016 Jan;53:135-43. doi: 10.1016/j.ejca.2015.09.014. Epub 2015 Dec 17.

PMID:
26707830

Supplemental Content

Support Center